thetrutides

TB-500

A thymosin beta-4 fragment studied for tissue repair

UPDATED 4 AUGUST 2026

TB-500 is widely sold for recovery and soft-tissue repair. It is worth being direct about the evidence: at the July 2026 PCAC hearing, FDA stated there are no studies on TB-500 itself, as distinct from the parent protein it derives from.

In Plain English

Your body makes a protein called thymosin beta-4 that helps tissue rebuild after injury. TB-500 is a short piece of that protein, made synthetically, on the theory that the fragment carries the useful part of the signal. Most of the encouraging research is on the full protein, not the fragment being sold — that gap is the single most important thing to understand about this compound.

What people use it for. Recovery and soft-tissue repair, usually alongside BPC-157 rather than on its own — the pairing is what most people mean by a recovery stack.

What to know before you buy. This is the compound where the certificate of analysis matters most. Because there is no agreed definition of what TB-500 is, two vials with the same label can contain genuinely different molecules. Ask for the sequence and the molecular weight, not just the purity percentage. There is also an unresolved theoretical question about whether a compound that promotes tissue growth could also support the growth of tissue you would rather not grow. Nobody has studied that in TB-500 either way.

What It's Used For

GOAL	WHAT THAT RESTS ON
Soft-tissue recovery	Repair and cell-migration signalling reported for thymosin beta-4, the larger parent protein
Flexibility and tissue quality	Reported in animal models of the parent protein
Stacking with BPC-157	The most widely used recovery pairing; the two act through different mechanisms

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.

How to Buy It

AVAILABLE IN THESE BLENDS

Wolverine 20mg — BPC-157 + TB-500	$95
GLOW 70mg — adds GHK-Cu	$100
KLOW 80mg — adds GHK-Cu + KPV	$110

Bulk pricing: 2-3 vials −5% | 4-6 vials −10% | 7-9 vials −15% | 10+ vials −20%

This compound is supplied as part of the blends above rather than as a standalone vial. **Ships sealed and lyophilized** — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

At a Glance

CLASS	Synthetic peptide fragment, typically described as a 17-amino-acid sequence from thymosin beta-4 (Tβ4)
KEY DISTINCTION	Tβ4 is a 43-amino-acid protein with its own research literature. TB-500 is a fragment and is **not** interchangeable with it
PRECLINICAL	Repair and angiogenesis signals reported in animal models, largely attributed to Tβ4 rather than the fragment
HUMAN DATA	No completed randomised controlled trial of TB-500
REVIEWED FOR	Wound healing
REGULATORY (US)	Not FDA-approved. PCAC recommended for 503A listing 23 July 2026; no FDA action taken
FORMAT	Sold within blends; also as a standalone vial

8-6-1	0	17 aa
PCAC VOTE	TB-500 RCTS	TYPICAL FRAGMENT

REGULATORY STATUS — READ THIS FIRST

On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted **8-6-1 to recommend** TB-500 (free base and acetate) for the Section 503A bulk drug substances list. That vote is **advisory only.** As of 4 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA's own scientific reviewers had recommended *against* all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency's decision is weaker here than normal. Several outlets have reported this as the FDA "clearing", "approving" or "adding" these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.

The Characterisation Problem

This is the issue FDA returned to repeatedly, and it is a practical buying concern rather than an abstract one. “TB-500” is a common name, not a defined substance. FDA noted that exact sequences and molecular weights vary between vendors, and asked the panel directly: when a prescriber writes for TB-500, does anyone actually know what the patient is receiving?

FDA’s Russ Wesdyk compared it to buying a car for a teenager on the manufacturer’s name alone and ending up with “a Volvo with NASCAR specs” — same nameplate, different specification underneath. The agency also stated it lacks authority to define what TB-500 *is*.

WHAT THIS MEANS FOR SOURCING

Because there is no settled sequence, a certificate of analysis is doing more work here than with most compounds. Verify the stated amino acid sequence and molecular weight on the COA rather than relying on the product name. Two vials both labelled TB-500 can legitimately contain different molecules.

What the Research Shows

The cancer question

Several panellists raised a possible cancer signal, on the mechanistic reasoning that a compound promoting angiogenesis and cell migration could in principle also support tumour progression. FDA acknowledged during the hearing that there are no studies on TB-500 itself addressing this. The concern is therefore theoretical and unresolved rather than demonstrated — but “unstudied” is not the same as “shown to be safe”, and FDA asked the panel to treat the absence of information as its own data point.

Why it is recommended anyway

The 8-6-1 vote is best read as a judgement about access rather than evidence. Members in the majority described bringing a decision patients are already making into a regulated framework of licensed pharmacies and testing. Dissenters cited the paucity of efficacy data, the tumour-progression overlap, and the proposed use as an injectable.

THE BOTTOM LINE

TB-500 has the weakest direct evidence base of the compounds recommended in July 2026. The supportive research largely belongs to a different, larger molecule. If you are evaluating this compound, the honest framing is a plausible mechanism inherited from Tβ4, no direct human trials, an unresolved theoretical cancer question, and real vendor-to-vendor variability in what is actually in the vial.

Also in the Range

Sold within **Wolverine**, **GLOW** and **KLOW**. All three already contain it, so these are alternatives to one another rather than additions.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** FDA PCAC meeting materials and briefing documents, 23-24 July 2026; Hyman, Phelps & McNamara FDA Law Blog, 24 and 28 July 2026; Mintz, 29 July 2026; Polsinelli, 22 April 2026.